Knights of Columbus Asset Advisors LLC Sells 8,110 Shares of Cencora, Inc. (NYSE:COR)

Knights of Columbus Asset Advisors LLC lowered its position in Cencora, Inc. (NYSE:COR) by 16.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 41,253 shares of the company’s stock after selling 8,110 shares during the quarter. Knights of Columbus Asset Advisors LLC’s holdings in Cencora were worth $9,269,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Sei Investments Co. increased its stake in Cencora by 5.2% in the fourth quarter. Sei Investments Co. now owns 321,877 shares of the company’s stock valued at $72,319,000 after acquiring an additional 16,039 shares during the last quarter. American Century Companies Inc. increased its stake in Cencora by 43.8% in the fourth quarter. American Century Companies Inc. now owns 862,637 shares of the company’s stock valued at $193,818,000 after acquiring an additional 262,823 shares during the last quarter. Mizuho Securities USA LLC increased its stake in Cencora by 46.9% in the fourth quarter. Mizuho Securities USA LLC now owns 16,621 shares of the company’s stock valued at $3,734,000 after acquiring an additional 5,309 shares during the last quarter. Sciencast Management LP bought a new position in Cencora in the fourth quarter valued at $243,000. Finally, Millstone Evans Group LLC bought a new position in Cencora in the fourth quarter valued at $131,000. Institutional investors own 97.52% of the company’s stock.

Insider Buying and Selling at Cencora

In other Cencora news, CAO Lazarus Krikorian sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $260.06, for a total transaction of $520,120.00. Following the completion of the transaction, the chief accounting officer now owns 20,154 shares in the company, valued at $5,241,249.24. This trade represents a 9.03 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Robert P. Mauch sold 4,970 shares of Cencora stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $255.00, for a total value of $1,267,350.00. Following the completion of the transaction, the chief executive officer now owns 51,070 shares of the company’s stock, valued at approximately $13,022,850. This trade represents a 8.87 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 11,970 shares of company stock worth $2,998,670 in the last quarter. 10.80% of the stock is owned by corporate insiders.

Cencora Stock Down 0.3 %

COR opened at $266.91 on Friday. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $271.08. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. The stock has a market cap of $51.76 billion, a price-to-earnings ratio of 37.97, a price-to-earnings-growth ratio of 1.31 and a beta of 0.51. The firm’s fifty day moving average is $250.62 and its 200 day moving average is $240.06.

Cencora (NYSE:COR) last released its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. On average, sell-side analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were issued a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 0.82%. The ex-dividend date of this dividend was Friday, February 14th. Cencora’s dividend payout ratio is presently 31.29%.

Analyst Upgrades and Downgrades

COR has been the subject of several analyst reports. Wells Fargo & Company upped their price target on shares of Cencora from $251.00 to $274.00 and gave the company an “equal weight” rating in a research report on Friday, March 14th. JPMorgan Chase & Co. upped their price target on shares of Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. StockNews.com upgraded shares of Cencora from a “hold” rating to a “buy” rating in a research report on Wednesday, March 12th. Mizuho initiated coverage on shares of Cencora in a research report on Wednesday, December 4th. They set an “outperform” rating and a $280.00 price target for the company. Finally, Evercore ISI upped their price target on shares of Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a research report on Thursday, February 6th. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $280.20.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.